Posted On: 03/22/2015 10:06:23 AM
Post# of 63828
Nearly 75% Of Biotechs Have No Earnings
With the red-hot, and making new record highs every day, biotech index - which together with AAPL is the main driver behind the Nasdaq's surge back over 5,000 - seemingly all anyone can talk about, we decided to layout the simple facts.
(Linked) is a chart of the 150 companies that make up the Nasdaq Biotech Index (NBI), broken down by Net Income.
Of the 150 companies, in the last 12 months only 41 had earnings, i.e., Net Income, amounting to just under $31 billion
Of this $31 billion in earnings, just 5 companies - Gilead, Amgen, Shire, Biogen and Celgene - had net income over $1 billion
Just these 5 biotechs represented 83% of all the earnings generated in the NBI
109 companies in the NBI lost money in the last 12 months.
In summary: only 41 companies in the index were profitable, which means 72.5% of biotechs lost money
83% of Biotech earnings were generated by just 12% of the companies
With the red-hot, and making new record highs every day, biotech index - which together with AAPL is the main driver behind the Nasdaq's surge back over 5,000 - seemingly all anyone can talk about, we decided to layout the simple facts.
(Linked) is a chart of the 150 companies that make up the Nasdaq Biotech Index (NBI), broken down by Net Income.
Of the 150 companies, in the last 12 months only 41 had earnings, i.e., Net Income, amounting to just under $31 billion
Of this $31 billion in earnings, just 5 companies - Gilead, Amgen, Shire, Biogen and Celgene - had net income over $1 billion
Just these 5 biotechs represented 83% of all the earnings generated in the NBI
109 companies in the NBI lost money in the last 12 months.
In summary: only 41 companies in the index were profitable, which means 72.5% of biotechs lost money
83% of Biotech earnings were generated by just 12% of the companies
(0)
(0)
